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Objective: To systematically review the methodology of general burden of disease studies. Three key questions
were addressed: 1) what was the quality of the data, 2) which methodological choices were made to calculate
disability adjusted life years (DALYs), and 3) were uncertainty and risk factor analyses performed? Furthermore,
DALY outcomes of the included studies were compared.
Methods: Burden of disease studies (1990 to 2011) in international peer-reviewed journals and in grey literature
were identified with main inclusion criteria being multiple-cause studies that quantified the burden of disease as
the sum of the burden of all distinct diseases expressed in DALYs. Electronic database searches included Medline
(PubMed), EMBASE, and Web of Science. Studies were collated by study population, design, methods used to
measure mortality and morbidity, risk factor analyses, and evaluation of results.
Results: Thirty-one studies met the inclusion criteria of our review. Overall, studies followed the Global Burden of
Disease (GBD) approach. However, considerable variation existed in disability weights, discounting, age-weighting,
and adjustments for uncertainty. Few studies reported whether mortality data were corrected for missing data
or underreporting. Comparison with the GBD DALY outcomes by country revealed that for some studies DALY
estimates were of similar magnitude; others reported DALY estimates that were two times higher or lower.
Conclusions: Overcoming “error” variation due to the use of different methodologies and low-quality data is a
critical priority for advancing burden of disease studies. This can enlarge the detection of true variation in
DALY outcomes between populations or over time.
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The burden of disease concept provides a conceptual
and methodological framework to quantify and compare
the health of populations using a summary measure of
both mortality and disability – the disability-adjusted
life year (DALY) [1,2]. Since the launch of the Global
Burden of Disease (GBD) study in 1993, the burden of
disease concept has been widely adopted by countries
and health development agencies alike to identify the
relative magnitude of different health problems. This
information serves as crucial input for debates about
priorities in the health sector.
Criticism of the GBD study focused on the construc-
tion of DALYs [3,4], particularly the social choices* Correspondence: s.polinder@erasmusmc.nl
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reproduction in any medium, provided the oraround age weights and severity scores of disabilities.
The GBD 2010 Study that is currently being conducted
responded to the critiques and recent improvements in
the field and includes significantly improved methods
for burden assessment, particularly for ranking risk
factors and disabilities [5,6]. It is expected that the
imminent publication of the GBD 2010 Study will result
in a new impulse to perform burden of disease studies.
A major strength of the burden of disease concept is
that it allows comparison between different health pro-
blems, between different years, and between countries.
In principle, the DALY approach should be used consist-
ently to provide comparable DALY estimates. However,
the technical approach of the GBD is complex, both in
concept and in application, and there are many meth-
odological alternatives, e.g., using alternative morbidity
estimates, life expectancies, or severity weights, whichl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the interpretation of results of burden of disease studies
requires detailed methodological knowledge.
General burden of disease studies are multiple-cause
studies that quantify the burden of disease as the sum of
the burden of all distinct diseases expressed in DALYs.
Until now, a systematic review of general burden of
disease studies and the underlying methodological
choices has not been conducted. This review was a first
step in the development of a protocol specifically for
burden of foodborne disease studies. This protocol com-
plements the GBD manual, as it addresses problems that
arise particularly when undertaking foodborne burden
of disease studies. The protocol was developed for
researchers that aim to undertake burden of foodborne
disease studies in the framework of the Foodborne Dis-
ease Burden Epidemiology Reference Group (FERG).
The FERG was established in 2007 by the World Health
Organization (WHO). The purpose of the group is to
advise WHO in their estimates of the global burden of
diseases commonly transmitted through food.
This systematic review aims to provide an overview of
the methodology of general burden of disease studies
using the DALY approach. In the review, the following
key questions were addressed: 1) what was the quality of
the data and were there any data gaps, 2) which meth-
odological choices were made in order to calculate years
of life lost due to mortality (YLL) and years lost due to
disability (YLD), and 3) which methods were used to
handle uncertainty and risk factor analysis. Furthermore,
DALY outcomes for specific disease and injury groups
resulting from the general burden of disease studies
were compared.
Methods
Selection criteria
In this review, burden of disease studies based on gen-
eral multiple-cause studies (including all diseases and
injuries) were included. Empirical studies in inter-
national peer-reviewed journals and grey literature pub-
lished in English in the period 1990 to 2011 were
included. Studies in established market economies and
low- and middle-income countries were also included.
The review is restricted to studies using the DALY as
a burden of disease measure, both country-specific
and worldwide.
Disability-adjusted life year
The DALY is calculated by adding YLL to morbidity
and disability, expressed in YLD. The DALY method-
ology is represented in a conceptual framework in
Figure 1.
YLL is calculated by summation of the number of fatal
cases (d) due to health outcome (x) in a certain periodmultiplied by the residual expected life expectancy (e) at
the age of death:
YLLx ¼ Σdx  ex
For the calculation of YLD an incidence or prevalence-
based approach can be used, which is highly dependent
on the availability of data. The incidence-based approach
quantifies both the burden of disease occurring during
the reference period and the burden accrued into the fu-
ture. A prevalence-based approach ascribes burden to
the age at which disability is lived.
YLDinc is calculated by multiplying the number of inci-
dent cases (I) at a certain age with health outcome (x)
by the duration of the health outcome (t) and the dis-
ability weight (dw) assigned to health outcome x:
YLDincx ¼ ΣIx  tx  dwx
YLDprev is calculated by multiplying the number of
prevalent cases (P) in age group (x) at a point in the
reference period with the disability weight (dw) assigned
to health outcome x:YLDprev x = Px × dwx These basic
formulas can be supplemented due to methodological
choices (e.g., expanding with discount factor and age-
weighting).
Data sources and search strategy
Searches of eligible studies were conducted in Medline
(PubMed), EMBASE, and Web of Science. Searches for
eligible grey literature were conducted in Google Scholar
and SIGLE (System for Information on Grey Literature
in Europe). All international peer-reviewed articles and
grey literature published in English in the period January
1990 to 2011 were included in the searches. Search terms
used for general burden of disease studies were: “burden
of disease, “disability adjusted life year,” “disability-
adjusted life year,” “DALY.” Keywords were matched to
database-specific indexing terms. In addition to database
searches, reference lists of review studies and articles
included in the review were screened for titles that
included key terms.
Data extraction
Relevant papers were selected by screening the titles
(first step), abstracts (second step), and entire articles
(third step) retrieved through the database searches.
During each step respectively, the title, abstract, or
entire article was screened to ensure that it met the selec-
tion criteria listed above. This screening was conducted
independently by two researchers (Suzanne Polinder
and Juanita Haagsma). Disagreement about eligibility
between the reviewers was solved through discussion.
Full articles were critically appraised by two reviewers
(Suzanne Polinder and Juanita Haagsma), using data
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Figure 1 Conceptual model.
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study population, details regarding the methods used to
calculate YLL and YLD, risk factor analysis, main conclu-
sions, and evaluation of results. Their reports were com-
pared and disagreements were resolved by discussion.
Results
Literature search
Figure 2 shows the flow diagram of the search of existing
burden of disease studies and main reasons for exclu-
sion. Eventually, 31 studies were included in the review.
Table 1 shows the studies that have been included for
the review. In Figure 3, the number of general burden of
disease studies is shown per WHO region. Four studies
were worldwide burden of disease studies [8-11].
What was the quality of the data and were there any
data gaps?
The availability and quality of mortality and morbidity
data strongly differs by country.
Most countries register the number of fatal cases as
well as the age and cause of death in national vital regis-
trations (see Table 1). Vital registration often had full
coverage, which means that the data are representative
for the population of these countries.
Where vital registration had less than 100% coverage it
is important to know whether the data had been extra-
polated to 100%. However, the majority of the studies
did not report whether the death statistics used had
100% coverage. Only 10 studies reported that they cor-
rected for underreporting of death statistics [8,10-18],
for instance with demographic projection models [14],or by using the average of several years of death statistics
to minimize stochastic variation [10,18].
Next to extrapolation in case of missing data, pro-
cedures such as reallocating of ill-defined deaths from
so-called “garbage codes” may be necessary. Problems
can arise from the routine use of specific codes in the
International Classification of Diseases (ICD) list where
information is incomplete. This can occur when medical
records are not fully considered or when medical practi-
tioners concerned with the specific cases are not con-
sulted during the process of completing the forms.
Certain codes then become overused and bias the rela-
tive importance attached to particular cases of death.
These codes are called “garbage codes.” The majority
of the studies (n=24; Table 2) reported corrections for
ill-defined deaths, partly by reallocation from garbage
codes. For instance, the Victorian Burden of Disease
study [19] redistributed the cardiovascular garbage codes
to ischemic heart disease, inflammatory heart disease,
and hypertensive heart disease in proportions that varied
by age. Notably, many studies did not report whether
mortality data were corrected for missing data, underre-
porting, or misclassification.
Which methodological choices were made in order
to calculate YLL and YLD
General burden of disease methods
An incidence- or prevalence-based method can be used
to quantify the burden of disease. In practice, it is often
difficult to rigidly apply the incidence or prevalence-
based approach and sometimes compromises must be
made. Most studies have followed an incidence-based
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Figure 2 Flow diagram of the search of existing burden of disease studies.
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not all incidence-based data could be gathered, and
partly the prevalence-based method was used.
The GBD developed a list of disease and injury causes
based on the ICD. Including all causes avoids the problems
of overinclusiveness of single-cause studies and incompat-
ible mortality claims for different causes. Most studies used
the GBD disease and injury causes, and sometimes some
causes were removed due to little relevance and other
causes were added to the list (Table 2). Three studies
developed their own disease and injury groups [20-22].
The original GBD study applied age-weighting and dis-
counting [23]. With age-weighting, the altering levels of
dependency with age are taken into account, meaning that
years lived at youngest and oldest age are given less weight.
Discounting means that future life years are assigned less
value than those lived today. This is based on the economic
concept that immediate profits are generally preferred over
benefits later in time [1]. Both age-weighting anddiscounting have been disputed, which is further described
in the discussion section. This debate is also translated in
the distinction in the use of both methodologies in the
included studies. Almost all studies (n=26) assigned less
value to future life years by using a discount factor. How-
ever, only half of the studies (n=17) performed age-
weighting in their study. It was not always stated whether
age-weighting and discounting were used [18,24].
Methods to calculate YLL
Country-specific or model life tables with life expectancy
data can be used to calculate YLLs. Most studies used
the Coale and Demeny West Level 26 and 25 life tables,
developed by GBD (n=23; Table 2). The West Level 26
and 25 life tables are global model life tables that have a
standard life expectancy at birth: 80.0 years for males
and 82.5 years for females [25]. Other studies used life
tables from their country (n=8) [18,21,26-31].
Table 1 Study characteristics of included studies
Author, Year (reference no.) Country1 WHO region Data sources mortality Data sources morbidity
Begg, 2008 [13] Australia WPRO Australian death registry from Australian Bureau of Statistics Disease registers, cohort and intervention studies
and surveys
Bowie, 1997 [22] South and West region,
England
EURO 1992 Office of Population Censuses and Surveys age-specific
mortality data
World bank study
Bradshaw, 2003 [14] South Africa AFRO 1) Statistics South Africa, 2) Population Register, 3) National
Injury Mortality Surveillance Study, 4) For children:
1996 census and the 1998 Demographic and Health Survey
The South African Birth Defects Surveillance System
Bundhamchareon, 2002 [16] Thailand SEARO Survey of Population Change Disease registers, routine databases or epidemiological
studies
Chapman, 2006 [41] Zimbabwe AFRO Vital Registration System and number of deaths for 1997
taken from a nationwide census
Local disease registers, surveys and routine health
service data supplemented by estimates from
epidemiological studies from other settings
Dodhia, 2008 [50] London, England EURO Local mortality data The GBD estimates from World Health Organization
were used
Hyder, 2000 [40] Pakistan EMRO Pakistan Demographic Survey of 1989, Pakistan Demographic
and Health Survey 1990–1991, National Health Survey of
Pakistan 1989–1994
More than 180 national and local data sources were
reviewed to obtain information on diseases in Pakistan
Innove Solutions, 1998 [51] West Pennine, England EURO National mortality data from Public Health Department West Pennine Health Authority morbidity data
Jankovic, 2007 [52] Serbia and Serbia
Montenegro
EURO Serbian Office of Statistics mortality database Disease registers, routine databases, and epidemiological
studies
Laaser, 2007 [38] Syria EMRO National mortality register, analysis of the WHO life table
of Syria and mortality sentinel surveillance
National databases
Lai, 2009 [27] Estonia EURO Vital registration of Statistics Estonia Estonian Health Insurance Fund database
Lopez, 2006 [9] Global Global Death registrations, population-based epidemiological
studies, disease registers, and notification systems.
Disease registers, epidemiological studies, health surveys,
and health facility data
Mathers, 2001 [28] Australia WPRO Australian death registry from Australian Bureau of Statistics Disease registers and epidemiological studies
Melse, 2000 [21] Netherlands Dutch death registration General practitioner registrations, national registries,
and population surveys
Michaud, 2006 [35] United States AMRO Mortality File from the National Center for Health
Statistics 1996
National health surveys, the National Hospital Discharge
Database, disease registers, and epidemiological studies
Murray, 1997 [10] Global 21 regions in
the world
Death registration systems, sample death registration systems,
epidemiological assessments, cause of death models
Disease registers, population surveys, epidemiological
studies, health facility data
Naghavi, 2009 [31] Iran EMRO data from the national death registry of Health Ministry ME Disease surveillance systems, hospital disease registries,
representative national surveys, subnational and
local studies.
Phua, 2009 [39] Singapore, Malaysia WPRO Registry of Births and Deaths National disease registers and surveillance or notification
systems, national health surveys, health services
utilization data
Pike, 2002 [30] Queensland, Australia WPRO Australian death registry from Australian Bureau of Statistics Australian BoD YLD data
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Table 1 Study characteristics of included studies (Continued)
SA Department of Health
Australia, 2005 [12]
South Australia WPRO Australian death registry from Australian Bureau of Statistics Disease registers and epidemiological studies
Somerford, 2004 [29] Western Australia WPRO Australian death registry from Australian Bureau of Statistics Australian BoD YLD data
Stevens, 2008 [26] Mexico AMRO National Mortality statistics Vital statistics, national censuses, health examination
surveys, and published epidemiological studies
Tobias, 2001 [20] New Zealand WPRO New Zealand Health Information Service mortality Disease registers, population surveys, hospital
discharge register
Ünüvar, 2004 [15] Turkey EURO Death statistics obtained from provincial and town centers
in Turkey, hospital records and Directorate General of
Security data
Population Census, Records obtained from government
agencies, National surveys, national and international
reports and articles
Victorian BOD, 2005 [19] Victoria, Australia WPRO Australian death registry from Australian Bureau of Statistics Disease registers, routine databases and population
health surveys
World Health Organization,
2008 [8]
Global 21 regions in
the world
Death registration systems, sample death registration systems,
epidemiological assessments, cause of death models
Disease registers, population surveys, epidemiological
studies, health facility data
World Health Organization,
2009 [11]
Global 21 regions in
the world
Death registration systems, sample death registration systems,
epidemiological assessments, cause of death models
Disease registers, population surveys, epidemiological
studies, health facility data
Yoon, 2007 [24] Korea SEARO The Korean National Health Insurance system Large normative cohort
Yusoff, 2004 [17] Malaysia WPRO Malaysian mortality data of the Department of Statistics
subdivided in four regions
Disease registries, routine databases and epidemiological
studies
Zhao, 2004 [18] Northern Territory,
Australia
WPRO Australian death registry from Australian Bureau of Statistics Disease registers, population surveys, expert opinions
Zhou, 2011 [36] Yunnan Province,
China
WPRO Medical death certificate information from Centers for Disease
Control and Prevention
Indirect method: YLD/YLL ratio for China taken from the
WHO World Health Report 2002
1 Country / region and country of the study population.
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Figure 3 Number of general burden of disease studies, per WHO region.
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A crucial aspect to calculating YLD is the disability
weight; a value ranging from 1, indicating worst imagin-
able health state equal to death, through 0, indicating
full health. Its value is based on the preferences stated
by a panel of judges towards a set of hypothetical health
states, expressing the relative undesirability of the health
state [32,33]. Several sets of disability weights exist, such
as the GBD disability weights [1] and the Dutch Disabil-
ity Weights (DDW) [34]. Most studies (n=27; Table 2)
used the GBD disability weights. Sixteen of these studies
combined the GBD weights with the DDW for disease
and injury causes that were not in the GBD study.
Four studies [14,29,35,36] derived YLD by applying the
ratio of YLD to YLL from one study to derive the YLDs
for their own study, which is common in burden of dis-
ease analyses for countries with limited data on disease
occurrence [25]. For instance, the Western Australian
Burden of Disease study [29] used this method to derive
the YLDs for residual conditions not specifically ana-
lysed, but which were grouped to complete a broad dis-
ease grouping (e.g., other cardiovascular conditions).Eight studies adjusted for comorbidity [12,13,16,19,20,
28,30,31]. The Australian burden of disease studies
[13,19,28,30] have developed methods to address the
issue of comorbidity for the common coexisting nonfatal
conditions (e.g., deafness, osteoarthritis, mental retard-
ation, diabetes). With this method, the difference be-
tween a composite weight for two coexisting conditions
and the weight for the more severe of the conditions is
calculated and used, rather than the weight of the milder
condition in its independent state. The disability weight
for the more severe condition remains unchanged.Which methods were used to handle uncertainty and
risk factor analysis?
Uncertainty analysis
Each burden of disease study contains uncertainty as
a result of possible imprecision in epidemiological data
(e.g., deaths, incidence, prevalence, severity), in the
parameter values used or due to methodological contro-
versy. None of the studies quantify uncertainty in epi-
demiological data. Uncertainty in the parameter values is
Table 2 Methods used to calculate YLL and YLD in general burden of disease studies
Author, Year
(reference no.)
General burden of disease methods YLL methodology YLD methodology
Incidence or
prevalence
based
approach
Disease and
injury cause
groups used
Were
missing
values
handled?
Discounting Age
weighting
Sensitivity
analysis
Risk
factor
analysis
Which life
tables used?
Reallocation
of ill-defined
death? (y/n)
Disability
weights
Distribution
by severity?
Adjustment
for comorbidity
GBD approach Incidence GBD list I, II, III Y Y Y Y Y Standard West
25 (males) and
26 (females)
Y GBD N N
Begg, 2008 [13] Incidence GBD list I, II, III Y Y Y Y Y Standard West
25 (females) and
26 (males)
Y GBD, DDW Y Y
Bowie, 1997 [22] Incidence Own developed
groups
n.a. Y Y N N Standard West
25 (females) and
26 (males)
N GBD N N
Bradshaw,
2003 [14]
Incidence Adapted GBD
list (removed
causes due to
little relevance)
Y Y Y Y N Standard West
25 (males) and
26 (females)
Y GBD1990,
GBD2000,
Audw, DDW
Y N
Bundhamcharoen,
2002 [16]
Incidence GBD list I, II, III Y Y Y Y N Standard West 26 Y GBD, DDW Y Y
Chapman,
2006 [41]
Incidence GBD list I, II, III Y Y Y Y N Standard West 26 Y GBD, Zimb N n.a.
Dodhia,
2008 [50]
Incidence Adapted GBD
list (removed
causes and
added own
groups)
Y Y N Y N Standard West 26 N GBD N N
Hyder,
2000 [40]
Incidence Adapted GBD
list (removed
causes and
added own
groups)
n.a. Y N Y N Standard West
25 (females) and
26 (males)
N GBD N N
Innove Solutions,
1998 [51]
Incidence Adapted GBD
list (removed
causes and
added own
groups)
N N N N N Standard West 26 Y GBD, DDW N n.a.
Jankovic,
2006 [52]
Incidence Adapted GBD
list (removed
causes due
to little
relevance)
Y Y Y Y N Standard West 26 n.a. GBD1990,
GBD2000,
DDW
Y N
Laaser, 2007 [38] Incidence and
prevalence
GBD list I, II, III n.a. Y Y Y N Standard West
25 (females) and
26 (males)
Y GBD1996,
GBD2000
n.a. N
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Table 2 Methods used to calculate YLL and YLD in general burden of disease studies (Continued)
Lai, 2009 [27] Prevalence GBD list I, II, III Y N N N N Standard life tables
of Estonia
N Estdw Y N
Lopez, 2006 [9] Incidence GBD list I, II, III n.a. Y N Y Y Standard West
25 (females) and
26 (males)
Y GBD n.a. N
Mathers,
2001 [28]
Incidence Adapted GBD
list (added own
groups)
Y Y N Y Y Australian standard
life tables
Y DDW, GBD Y Y
Melse, 2000 [21] Prevalence Own developed
groups
n.a. N N Y N Dutch life tables
for 1994
Y DDW Y N
Michaud,
2006 [35]
Incidence Adapted GBD
list (removed
causes and
added own
groups)
Y Y Y Y N Standard West
level 25 and 26
Y GBD Y N
Murray,
1997 [10]
Incidence GBD list I, II, III n.a. Y Y Y Y Standard West
level 25 and 26
Y GBD n.a. N
Naghavil,
2009 [31]
Incidence Adapted GBD
list (removed
causes and
added own
groups)
Y Y Y N N Iran life expectancy Y GBD, DDW n.a. Y
Phua, 2009 [39] Incidence Adapted GBD
list (removed
causes and
added own
groups)
Y Y N N N Standard West
25 (females) and
26 (males)
Y GBD, DDW,
Audw
Y N
Pike, 2002 [30] Incidence Adapted GBD
list (removed
causes and
added own
groups)
n.a. Y N N N Australian standard
life tables
n.a. GBD, DDW Y Y
SA Department
of Health
Australia,
2005 [12]
Incidence Adapted GBD
list (added own
groups)
Y Y Y Y Y Australian standard
life tables
Y GBD, DDW Y Y
Somerford,
2004 [29]
Incidence GBD list I, II, III N Y Y Y Y Australian standard
life tables
Y N, YLL:YLD N N
Stevens,
2008 [26]
Incidence GBD list I, II, III n.a. Y Y N Y Standard life tables
of Mexico
Y GBD N N
Tobias, 2001 [20] Incidence Own developed
groups
Y Y Y Y Y Standard West
25 (females) and
26 (males)
n.a. DDW, GBD,
Audw,
EQ5Ddw
Y Y
Ünüvar, 2006 [15] Incidence GBD list I, II, III Y Y Y Y Y Standard West Y GBD, DDW Y N
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Table 2 Methods used to calculate YLL and YLD in general burden of disease studies (Continued)
Victorian
BoD study,
2005 [19]
Incidence Adapted GBD
list (removed
causes and
added own
groups)
Y Y N Y Y Standard West
25 (females) and
26 (males)
Y DDW, GBD,
EQ5D,
Audw
Y Y
World Health
Organization,
2008 [8]
Incidence GBD list I, II, III Y Y Y Y Y Standard West
level 25 and 26
Y GBD N N
World Health
Organization,
2009 [11]
Incidence GBD list I, II, III Y Y Y Y Y Standard West
level 25 and 26
Y GBD N N
Yoon, 2007 [24] n.a. Adapted GBD
list (removed
causes and
added own
groups)
Y n.a. n.a. Y N Standard West Y KORdw Y N
Yusoff, 2004 [17] Incidence GBD list I, II, III Y Y N N N Standard West
25 (females) and
26 (males)
Y GBD, DDW Y N
Zhao, 2004 [18] Incidence GBD list I, II, III n.a. n.a. n.a. N N Australian standard
life tables
Y DDW, GBD n.a. N
Zhou, 2011 [36] Prevalence Adapted GBD
list (removed
causes)
n.a. Y n.a. N N Standard West Y N, YLL:YLD n.a. N
Abbreviations disability weights: Disability weights: GBD1990/GBD 1996 = Global Burden of Disease disability weights 1990 [1], GBD2000 = Global Burden of Disease disability weights 1990 supplemented with Dutch Disability
weighs, DDW= Dutch Disability weights [53], AUdw = Australian NBD disability weights [25], Zimb = disability weights based on preferences of Zimbabwe [41], KORdw= Korean disability weights [24], Estdw = Estonian disability
weights [27], EQ5Ddw = EQ5D disability weights [20].
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These studies test whether plausible changes in values of
the main variables affect the results of the analysis [1].
Most studies showed how the results of their study var-
ied when a discount rate changes, and some studies also
examined the influence of the use of age-weighting,
the effect of uncertainty in the disability weights, and/or
uncertainty in the incidence data.Risk factor analysis
A risk factor is an attribute or exposure that is causally
associated with an increased probability of a disease or
injury [1]. Regarding the causal attribution of the burden
of disease, one can either attribute it to a single cause
(categorical attribution) or to a group of causes (coun-
terfactual attribution). The latter can be analyzed using
counterfactual analysis. With counterfactual analysis, the
current or future disease burden is compared with the
burden of disease that would be expected under an alter-
native hypothetical scenario, the counterfactual scenario,
to estimate the effects of disease(s) or risk factor(s) [37].
Twelve studies performed risk factor analyses
[8-13,15,19,20,26,28,29]. Risk factors that were analyzed
were related to the effect of lifestyle factors (such as
tobacco smoking, physical inactivity, alcohol consump-
tion, diet, unsafe sex, and intimate partner violence),
physiological states (such as obesity, high blood pressure,
and high cholesterol) and also societal conditions (such
as occupational exposures and air pollution) on the
burden of disease.Comparison of disability-adjusted life year outcomes for
specific disease and injury groups
The total burden due to diseases and injuries varies
enormously between the included studies. The highest
burden of disease was found in Pakistan (45,600 DALYs
per 100,000) and Zimbabwe (41,900 DALYs per 100,000).
The lowest burden of disease was estimated in Queensland
(10,700 DALYs per 100,000) and Singapore (10,400 DALYs
per 100,000) (Table 3). The differences in total DALYs
between countries can partly be explained by differences in
exposure to risk factors. For example, almost half of the
total burden of disease in Zimbabwe is due to HIV and
diarrhea. These diseases are rare in developed countries. In
most developed countries the highest burden is caused by
cardiovascular diseases, followed by road traffic injuries and
depression.
Comparison with the GBD DALY outcomes by coun-
try revealed that DALY estimates were of similar magni-
tude in some studies (e.g., for Syria [38], USA [35],
Singapore [39], and Turkey [15]). Other studies reported
DALY estimates that were two times higher [27,40] or
two times lower [41] than the GBD study (Table 3).Notably, four of the Australian burden of disease
studies found comparable total DALY outcomes (be-
tween 13,220 and 13,700) [12,13,19,28], where the GBD
reported 9,894 as total DALYs for Australia.
Discussion
We systematically reviewed 31 general burden of disease
studies using the DALY approach and performed a qual-
ity assessment of the methodology used. We found that
studies generally followed the GBD approach, but that
large differences exist in methodology. Most studies
used the incidence-based approach (80%), and almost
all studies classified disease and injury groups as defined
by the GBD. Half of the studies used age-weighting,
whereas 80% of the studies used discounting.
As all systematic reviews, our study has some limita-
tions. Reviewing the literature in the field of “burden of
disease” studies was complicated by a wide variety of ter-
minology for burden of disease. Consequently, some
relevant publications may have been missed. To enhance
the identification of relevant burden of disease studies
we have used a variety of literature databases and
keywords were matched to database-specific indexing
terms. Furthermore, this review is limited to the English
language. Therefore, relevant studies in other languages
(e.g., Spanish [42,43]) are excluded. In the databases that
were reviewed, we found a limited number of studies
that included all diseases and injuries. An explanation
for this finding may be that the use of the DALY is con-
troversial and accompanied by theoretical concerns [44].
Practical concerns, such as lack of resources and avail-
able data sources and/or expertise, may also be a reason
for researchers’ apprehension to perform multiple-cause
burden of disease studies.
Quality of the data and were there any data gaps
The main issue in burden of disease studies is access to
complete, consistent, and comparable epidemiological
data. Summary measures of population health, such as
the DALY, are only as good as the weakest link in the
chain, which is the epidemiological evidence [45]. Most
studies derived numbers of incident cases directly from
disease registers, routine databases, or epidemiological
studies. Furthermore, some studies used a combination
of incidence and prevalence-based data because, for
most conditions, only prevalence data were available.
The calculation of mortality burden is straightforward,
and the precision of the estimates of YLL depends
almost entirely on the quality of data on underlying
causes of death. Although great improvements in report-
ing, coding, and classification of mortality have been
made, significant challenges remain. The infrastructure
for mortality and health databases varies considera-
bly around the world [1,46]. Developed regions have
Table 3 DALY outcomes for specific disease and injury groups (per 100,000 persons)
Author (ref no.) Country GBD study
all causes*
Study outcome
All causes Cardiovascular
diseases
Road traffic
injury
Diabetes
Mellitus
Depression HIV/AIDS
Begg [13] England Australia 9,894 13,240 2,380 930 720 1,760
Bowie [22] England 11,012 n.a. n.a. n.a. n.a. n.a. n.a.
Bradshaw [14] South Africa 46,137 36,100 n.a. 2,800
(all unintentional)
n.a. n.a. 10,210
Bundhamchareon [16] Thailand 20,216 13,710 380 893 624 342 1,900
Chapman [41] Zimbabwe 82,801 41,930 293 461 n.a. 2,350 20,380
Dodhia [50] England 11,012 13,400 2,300 n.a. n.a. 3,220 n.a.
Hyder [40] Pakistan 26,693 45,630 2,420 n.a. 1,170 n.a. 109
Innove Solutions [51] England 11,012 n.a. n.a. n.a. n.a. n.a. n.a.
Jankovic [52] Serbia /Serbia
Montenegro
14,562 n.a. 1,800 1,800 3,000 8,800 100
Laaser [38] Syria 16,167 14,700 3,700 1,120 610 840 n.a.
Lai [27] Estonia 16,212 32,700 5,700 n.a. n.a. n.a. n.a.
Lopez [9] Global Vary by region n.a. n.a. n.a. n.a. n.a.
Mathers [25] Australia 9,894 13,700 2,400 300 410 510 n.a.
Melse [21] Netherlands 9,948 16,000 2,720 460 540 710 100
Michaud [35] USA 12,844 12,420 1,730 520 n.a. n.a. 360
Murray [10] Global Vary by region n.a. n.a. n.a. n.a. n.a.
Naghavi [31] Iran 19,432 21,570 1,840 1,960 n.a. 900 n.a.
Phua [39] Singapore 10,111 10,400 2,050 360
(all unintentional)
1,130 1,200 n.a.
Pike [30] Queensland 9,894 10,710 2,260 240 320 1,400 8
SA Dep Health,
2005 [12]
Australia 9,894 13,220 2,700 950 400 1,800 n.a.
Somerford [29] Australia 9,894 n.a. n.a. n.a. n.a. n.a. n.a.
Stevens [26] Mexico 9,894 14,501 450 700 510 900 n.a.
Tobias [20] New Zealand 10,642 15,100 3,620 450 574 1,810 n.a.
Ünüvar [15] Turkey 16,307 14,790 2,070 355 280 590 n.a.
Victorian BOD [19] Australia 9,894 13,600 860 230 1,120 860 25
WHO, 2008 [8] Global Vary by region n.a. n.a. n.a. n.a. n.a.
WHO, 2009 [11] Global Vary by region n.a. n.a. n.a. n.a. n.a.
Yoon [24] Korea 22,128 n.a. 1,490 n.a. 990 1,140 n.a.
Yusoff [17] Malaysia 16,638 n.a. n.a. n.a. n.a. n.a. n.a.
Zhao [18] Australia
(non-aboriginals)
9,894 18,320 2,600 2,580
(all unintentional)
440 3,060 n.a.
Zhou, 2011 [36] China 15,750 12,270 1,200 1,470
(all unintentional)
90 n.a. n.a
* age-standardized DALY per 100,000 by country. Source: Global Burden of Disease study 2004. http://www.who.int/healthinfo/global_burden_disease/
estimates_country/en/index.html.
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through World Wide Web-based queries. Other coun-
tries maintain tabulated mortality statistics that are not
integrated into a utilizable database, and many develop-
ing countries have paper-based systems with rates basedon projections and estimates rather than actual counts
[46]. The data challenges that result from disparities
in the level of health infrastructure yield rates that can
be difficult to compare. Furthermore, differences in
death certification systems, methods of data collection,
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national comparisons.
Methodological choices
The calculation of the morbidity component of the bur-
den of disease, expressed in YLD, requires extensive epi-
demiological modelling and is often based on a diverse
range of data sources, literature research, and/or expert
opinion. The resulting YLD estimates depend highly on
the specific model being applied and the type of data
underlying this model.
Most studies used the GBD 1996 disability weights, in
many cases supplemented by DDW. The GBD disability
weights cover a wider range of conditions than covered
by the DDWs, but are generally less specific in terms of
the disease and sequelae categories to which they refer.
The set of DDW covers a more restricted range of con-
ditions compared to the GBD 1996 disability weights,
but it differentiates more finely between condition stages
and severities, thus allowing more detailed disease mod-
els in estimating the YLD than is possible with the GBD
weights [47]. For example, DDWs are often used for
HIV/AIDS and organ disorders. For the GBD 2010
Study, new disability weights are being derived [6].
In the original GBD study, discounting and age-
weighting are applied. Both age-weighting and discount-
ing have been disputed. The use of age-weighting is
discussed, since lost years of healthy life are assumed to
be of equal value regardless of the age at loss, the
absence of empirical foundation and validation, and
because the age weights do not convey actual social
values as this practice is controversial [3,48]. Discount-
ing has been disputed because its application results in a
lower efficiency of prevention programs, whereas not
discounting, or the use of a low discount rate – lower
than the discount rate used for the costs – favors pre-
ventive measures due to benefit in the far future [32].
This discussion is reflected in different choices to use
discounting and age-weighting between studies.
To measure the gap between actual population health
and an ideal, most studies used the global standard life
expectancy (West Level 26 and 25 life tables) as used by
the GBD study. These life tables contain the relevant
expectancies for each age and sex grouping. However,
they have the disadvantage that they are abridged period
life tables, chiefly using five-year age groupings and an
upper-age category of 85+ [28]. The use of cohort life
expectancies with more complete underlying popula-
tion data and more complex methods, as done for two
Australian studies [12,28], resulted in more accurate and
slightly different life expectancy measures. The use of
the global standard life expectancy figures is recom-
mended to enlarge the comparability with GBD studyoutcomes, but a sensitivity analysis using more detailed
country-specific life expectancies is recommended.Comparison of DALY outcomes
The sensitivity of DALYs, defined by the relative contri-
butions of “true” and “error” variation, is assumed to be
low. Potential sources of true variation include differ-
ences in the size and structure of populations, real dif-
ferences in disease epidemiology between populations or
over time, and differences in disability weights. Error
variation may originate from the use of different
methodologies (e.g., for discounting and age-weighting,
disability weights) and from low-quality mortality and
morbidity data. The detection of true variation is the
focus of interest when estimating the burden of disease
in DALYs. However, error may limit the power to detect
true differences between populations [49]. Therefore, at
the moment burden of disease studies are not compar-
able, nor are disease rankings as these are affected by
methodological variation as well.Conclusions and recommendations
Burden of disease analyses provide a unique perspective
on health, one that integrates fatal and nonfatal out-
comes, yet also allows the two classes of outcomes to be
examined separately. Furthermore, burden of disease
studies may provide a valuable insight into the scope for
further health gains on the global or country level. This
information will assist in taking up the future challenges
posed by an aging population, by changes in disease and
risk factor patterns, and by the increasing costs of health
services [28]. Linking burden of disease analyses to cost
effectiveness studies of interventions for major health
problems will allow these interventions to be judged
both in terms of cost effectiveness, and their relative
impacts in reducing the burden of disease and ill health
at the population level. Furthermore, burden of disease
studies may shed light on crucial data gaps and facilitate
priority setting in research.
However, large differences in used methodology exist
between general burden of disease studies. Because of
the methodological variation between studies it is diffi-
cult to assess whether differences in DALY estimates
between the studies are due to actual differences in
population health or whether these are the result
of methodological choices. Overcoming this methodo-
logical rigor between burden of disease studies using
the DALY approach is a critical priority for advancing
burden of disease studies. Harmonization of the method-
ology used and high-quality data can enlarge the detec-
tion of true variation in DALY outcomes between
populations or over time.
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logical rigor is particularly important in view of the
imminent launch of the GBD 2010 Study, which is
expected to result in a new impulse for the performance
of burden of disease studies. It is a challenge for the
GBD to develop more detailed harmonization proce-
dures and clear guidelines to increase methodological
improvements and enhanced comparability of general
burden of disease studies.
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